Anti-PD-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma

Table 3 Treatment-related adverse events

	Any grade	Grade≥3
Any	17 (47.2)	5 (13.9)
Hematologic toxic effects
Decreased white-cell count	8 (22.2)	0
Decreased lymphocyte	8 (22.2)	2 (5.6)
Decreased neutrophils	6 (16.7)	0
Anemia	2 (5.6)	0
Decreased platelet count	1 (2.8)	1 (2.8)
Liver function
Increased ALT	4 (11.1)	0
Increased AST	3 (8.3)	0
Hypoalbuminemia	2 (5.6)	0
Nonhematologic toxic effects
Reactive cutaneous capillary endothelial proliferation	9 (25.0)	0
Rash	5 (13.9)	0
Abdominal pain	5 (13.9)	0
Fatigue	5 (13.9)	0
Decreased appetite	5 (13.9)	0
Nausea	4 (11.1)	0
Biliary tract infection	4 (11.1)	0
Fever	4 (11.1)	0
Proteinuria	2 (5.6)	0
Hypothyroidism	2 (5.6)	0
Vomiting	2 (5.6)	0
Diarrhea	2 (5.6)	0
Bullous dermatitis	1 (2.8)	1 (2.8)
Deep-vein thrombosis	1 (2.8)	1 (2.8)

Data are n (%). Adverse events were graded according to Common Terminology Criteria for Adverse Events version 5.0
ALT alanine aminotransferase, AST aspartate aminotransferase

ISSN: 1741-7015